Coburg, ON-based
FSD Pharma Inc. (CSE: HUGE) has announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR.
FSD announced on September 1st, that it has submitted to the U.S. Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19 – the disease caused by the SARS-CoV-2 virus.
Click
here for full press release.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.